# Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease

> **NCT02685683** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 18 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** GED-0301

## Key facts

- **NCT ID:** NCT02685683
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-04
- **Primary completion:** 2017-09-25
- **Final completion:** 2017-11-09
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor following a recommendation from external DMC to terminate the ongoing Phase 3 CD studies; there were no new emergent safety findings
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02685683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02685683, "Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02685683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*